NCT03804424 2024-11-12
64Cu-LLP2A for Imaging Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated
Clinical Trials
3 trialsNCT04467281 2022-07-01
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 2 Withdrawn
NCT03665155 2021-07-30
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed